Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concomitant vinorelbine and nimotuzumab for newly diagnosed childhood and adolescence diffuse intrinsic pontine glioma (DIPG).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513654-30-00

Acronym

DIPG

Enrollment

Registered

2024-06-26

Start date

2015-11-04

Completion date

Unknown

Last updated

2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse intrinsic pontine glioma

Brief summary

Number of best responses (complete and partial responses) up to week 36 will be calculated in the conventional and experimental irradiation arms, and the comparison between the response rates will be performed

Detailed description

First progression of desease, first recurrence, secondary malignancy, death

Interventions

DRUGNIMOTUZUMAB

DRUGNAVELBINE 10 mg/ml concentrato per soluzione per infusione

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Number of best responses (complete and partial responses) up to week 36 will be calculated in the conventional and experimental irradiation arms, and the comparison between the response rates will be performed	—

Secondary

Measure	Time frame
First progression of desease, first recurrence, secondary malignancy, death	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026